BLEEDING AND THROMBOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA

Chapter 080. Cancer Cell Biology and Angiogenesis (Part 5) Targeting BCR-ABL with Imatinib: Proof of Principle The protein product of the Philadelphia chromosome occurs in all patients with chronic myeloid leukemia (CML) and in ~30% of patients with adult acute[r]

Tissue factor pathway inhibitor (TFPI) is a plasma protease inhibitor that regulates the TF-induced extrinsic pathway of coagulation. TFPI inhibits the TF/FVIIa/FXa complex, essentially turning off the TF/FVIIa initiation of coagulation, which then becomes dependent on the "amplification loop" via F[r]

Chapter 059. Bleeding and Thrombosis (Part 8) Screening Assays The most commonly used screening tests are the PT, aPTT, and platelet count. The PT assesses the factors I (fibrinogen), II (prothrombin), V, VII and X (Fig. 59-6). The PT measures the time for clot fo[r]

aspirin effect on platelet function as assessed by aggregometry can persist for up to 7 days, although it has frequently returned to normal by 3 days after the last dose. The effect of other NSAIDs is shorter, as the inhibitor effect is reversed when the drug is removed. Many herbal supplements can[r]

Afibrinogenemia Defects of Platelet Secretion Decreased cyclooxygenase activity Drug-induced (aspirin, nonsteroidal anti-inflammatory agents) Inherited Granule storage pool defects Inherited Acquired Nonspecific drug effects Uremia Platelet coating (e.g., paraprotein, penicillin) Defect of[r]

tissue factor (TF) exposure and activation through the classic extrinsic pathway, but with critically important amplification through elements of the classic intrinsic pathway, as illustrated in Fig. 59-1. These reactions take place on phospholipid surfaces, usually the activated plate[r]

Myeloid leukemia may be classified as Acute Myeloid Leukemia (AML) or Chronic Myeloid Leukemia (CML) based on its rate of progression. Administration of drugs is the best modality to treat myeloid leukemia, Imatinib mesylate (IM) and cytarabine (cyt) for CML and AML respectively. However, these drug[r]

some malignant adherent human and rat cell lines [1]and against spontaneous mammary tumors in HER-2transgenic mice [2]. We have previously found that itenters cells via lipid-rafts, interacts directly with BID, apro-apoptotic BH3-only Bcl-2 family protein, andinduces apoptosis [[r]

Chapter 104. Acute and Chronic Myeloid Leukemia (Part 4) Clinical Presentation Symptoms Patients with AML most often present with nonspecific symptoms that begin gradually or abruptly and are the consequence of anemia, leukocytosis, leukopenia or leukocyte dysfunction, o[r]

, 2 mM DTT, and pro-tease inhibitors [1 mM phenylmethylsulfonyl fluoride(PMSF), 1 mg/mL l eupeptin, and 1 m g/mL antipain].Aliquots of the homogenates (40 μg total protein/lane)were loaded on SDS-polyacrylamide gels at the appro-priate concentrations. Electrophoresis was perform ed at1[r]

Chapter 078. Prevention and Early Detection of Cancer (Part 3) Cancer Chemoprevention Chemoprevention involves the use of specific natural or synthetic chemical agents to reverse, suppress, or prevent carcinogenesis before the development of invasive malignancy. Cancer develops through an ac[r]

sequential courses of high-dose cytarabine, autologous stem cell transplant (SCT), high-dose combination chemotherapy with allogeneic SCT, or novel therapies, based on their predicted risk of relapse (i.e., risk-stratified therapy). Patients with APL usually receive tretinoin together with anthracyc[r]

feature associated with a lower CR rate and shorter survival time. The CR rate is lower in patients who have had anemia, leukopenia, and/or thrombocytopenia for >3 months before the diagnosis of AML when compared to those without such a history. Responsiveness to chemothe[r]

of the cells. Pharmacologic doses of the Rar α ligand, all-trans-retinoic acid (tretinoin), relieve the block and promote differentiation (see below). Similar examples exist with a variety of other balanced translocations and inversions, including the t(8;21), t(9;11), t(6;9), and